Halozyme Therapeutics (HALO) Stock Forecast, Price & News

Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

Is Halozyme Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics or view top-rated stocks.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Halozyme Therapeutics.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by $0.02. The biopharmaceutical company earned $117.30 million during the quarter, compared to analyst estimates of $128.25 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 132.71% and a net margin of 92.23%. The business's revenue was up 31.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 EPS.
View Halozyme Therapeutics' earnings history.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided EPS guidance of $2.05-$2.20 for the period, compared to the consensus earnings per share estimate of $2.23. The company issued revenue guidance of $530.00 million-$560.00 million, compared to the consensus revenue estimate of $566.18 million.

What price target have analysts set for HALO?

4 Wall Street analysts have issued 1-year target prices for Halozyme Therapeutics' shares. Their forecasts range from $42.00 to $58.00. On average, they anticipate Halozyme Therapeutics' share price to reach $51.50 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for Halozyme Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:

• Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., Pres, CEO & Director (Age 59, Pay $1.65M)
• Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 58, Pay $779.55k) (LinkedIn Profile)
• Ms. Nicole LaBrosse, Sr. VP & CFO (Age 39)
• Ms. Melinda Hutcheon, Director of Investor Relations & Corp. Communications
• Mr. Mark Snyder Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Ms. Amy Marinne Fox, VP of HR
• Dr. Steve Knowles MBBS, Chief Medical Officer
• Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management
• Dr. Christopher Bryant Ph.D., Sr. VP of Technical Operations & Chief Manufacturing Officer (Age 61)
• Ms. Fionnuala Doyle, Sr. VP & GM of ENHANZE

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees.

Who are some of Halozyme Therapeutics' key competitors?

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of HALO's competitors.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.62%), William Blair Investment Management LLC (3.88%), Invesco Ltd. (3.86%), Snyder Capital Management L P (2.93%), Northern Trust Corp (1.63%) and Loomis Sayles & Co. L P (1.59%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics.

Which institutional investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Skandinaviska Enskilda Banken AB publ , Vanguard Group Inc., Invesco Ltd., Federated Hermes Inc., UBS Group AG, WINTON GROUP Ltd, and Eagle Asset Management Inc.. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, Jean-Pierre Bizzari, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Halozyme Therapeutics stock?

HALO stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Loomis Sayles & Co. L P, Bernzott Capital Advisors, Sectoral Asset Management Inc., GW&K Investment Management LLC, Russell Investments Group Ltd., First Light Asset Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Halozyme Therapeutics or or view top insider-buying stocks.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $44.82.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics has a market capitalization of $6.18 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $2.989990 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

Halozyme Therapeutics employs 145 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?

The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

When was Halozyme Therapeutics founded?

Halozyme Therapeutics was founded in 1998.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at [email protected], or via fax at 858-704-8311.